GYRE — GYRE THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1124105 ·
Last close
$5.75
Market Cap
$641.06M
52W High
$8.09
52W Low
$5.44
ADV30
95,297
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 22,519,000 | 21,292,000 | -6,802,000 | -8,691,000 | 162,015,000 | 37,501,000 | 25,030,000 |
| Dec 2025 | 37,195,000 | 35,452,000 | 120,000 | -1,723,000 | 166,132,000 | 37,070,000 | 23,850,000 |
| Sep 2025 | 30,564,000 | 28,936,000 | 6,926,000 | 3,610,000 | 159,384,000 | 40,402,000 | 21,969,000 |
| Jun 2025 | 26,771,000 | 25,620,000 | 2,172,000 | 442,000 | 152,646,000 | 36,491,000 | 23,203,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,010,000
Investing CF
$-474,000
Financing CF
$24,378,000
CapEx
$-1,923,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.01
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-68,426,000
Inventory
$10,171,000
Receivables
$36,946,000
ST Investments
$15,355,000
EBIT TTM
$11,491,000
Pretax Income TTM
$14,436,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$117,049,000
EBITDA
$5,073,000
Free Cash Flow
$9,599,000
Enterprise Value
$512,079,680
Total Cash
$49,808,000
Total Debt
$823,000
Shares Out
111,488,849
Trailing EPS
$-0.08
Book Value
$1.11
ROE
-3.1%
ROA
1.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 116,588,000 | 11,491,000 | 5,027,000 | 166,132,000 | 23,850,000 | — | 1,010,000 |
| Dec 2024 | 105,757,000 | 16,229,000 | 12,085,000 | 125,406,000 | 27,004,000 | — | -3,641,000 |
| Dec 2023 | 113,450,000 | 19,213,000 | -92,933,000 | 116,539,000 | 102,590,000 | — | 25,892,000 |
| Dec 2022 | 102,290,000 | 9,203,000 | 2,302,000 | 84,753,000 | 12,536,000 | — | 10,677,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.06
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $5.75 · call volume: 1 · put volume: 1Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $648.07M | $8.09 | — |
| NGNE | Neurogene Inc. | $656.17M | $32.89 | — |
| CTMX | CytomX Therapeutics, Inc. | $674.88M | $3.10 | — |
| STTK | Shattuck Labs, Inc. | $675.24M | $7.07 | — |
| NVCT | Nuvectis Pharma, Inc. | $678.43M | $21.52 | — |
News headlines (Yahoo Finance, 1h cache)
Gyre Therapeutics Appoints Three New Members to its Board of Directors
2026-07-16 20:05 · Yahoo
US High Growth Tech Stocks To Watch
2026-05-28 17:38 · Yahoo
New Strong Sell Stocks for May 27th
2026-05-27 12:18 · Yahoo
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
2026-05-12 20:05 · Yahoo
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 11:45 · Yahoo
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
2026-05-07 10:00 · Yahoo
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
2026-05-04 12:47 · Yahoo
Exploring Three High Growth Tech Stocks In The US Market
2026-03-27 17:38 · Yahoo
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
2026-03-17 11:00 · Yahoo
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
2026-03-12 11:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.